S-1/A: Scientific Industries Files S-1/A for Resale of 3.1 Million Shares, Highlights Bioprocessing Growth Strategy Amidst Continued Losses and Going Concern Warning

Scientific Industries, Inc. filed an S-1/A registration statement for the resale of up to 3.1 million shares of common stock by selling stockholders, emphasizing its strategic shift towards the Bioprocessing Systems segment despite ongoing net losses and a stated need for additional funding to continue as a going concern.

Summary

• The company filed an S-1/A registration statement for the resale of up to 3,100,000 shares of common stock by identified selling stockholders.
• The company will not receive any proceeds from the sale of shares by the selling stockholders, but will receive proceeds from the exercise of warrants.
• A private placement transaction was completed on April 18, 2025, involving the sale of 1,050,000 shares of Common Stock and warrants to purchase an additional 1,550,000 shares (including 500,000 pre-funded warrants) for a total consideration of $1,550,000.
• The company operates in two segments: Benchtop Laboratory Equipment, which is stable and profitable, and Bioprocessing Systems, which is the focus of the company's growth strategy and investment.
• A net loss of $1,778,500 was incurred for the three months ended March 31, 2025, an improvement from a $2,051,600 loss for the same period in 2024, primarily due to cost-cutting initiatives in the Bioprocessing Systems Operations segment.
• A net loss of $6,445,400 was recorded for the year ended December 31, 2024, a reduction from $9,086,500 for the year ended December 31, 2023, attributed to decreased expenses from operational cost reductions, mainly in Bioprocessing Systems.
• Total net revenues decreased by $77,000 (3.1%) to $2,406,500 for the three months ended March 31, 2025, compared to $2,483,500 for the prior year period, primarily due to a decrease in Bioprocessing Systems revenues offset by an increase in Benchtop Laboratory Equipment sales.
• Total net revenues for the year ended December 31, 2024, decreased by $398,900 (3.6%) to $10,712,600 from $11,111,500 in 2023, reflecting an increase in Bioprocessing Systems products offset by a larger decrease in Benchtop Laboratory Equipment operations.
• The company had an accumulated deficit of $35,709,000 as of March 31, 2025.
• Management believes that current operating cash flow, cash on hand, and available line of credit are not sufficient to fund cash requirements over the next twelve months, indicating a need for additional capital to continue as a going concern.

Sentiment

Score: 3

Explanation: The document presents a challenging financial picture, marked by persistent net losses, a significant accumulated deficit, and an explicit 'going concern' warning due to insufficient liquidity for the next 12 months. While cost-cutting efforts have reduced losses and the bioprocessing segment shows some revenue growth, the overall financial health and competitive landscape are highly unfavorable. The capital raise mentioned is primarily for resale by selling stockholders, not a direct infusion of capital for the company's operations from the offering itself, although warrant exercises could provide some funds. The risks outlined are substantial and pervasive.

Positives

• Net loss for the three months ended March 31, 2025, decreased to $1,778,500 from $2,051,600 in the prior year, primarily due to cost-cutting initiatives in the Bioprocessing Systems Operations segment.
• Net loss for the year ended December 31, 2024, decreased to $6,445,400 from $9,086,500 in the prior year, due to decreased expenses resulting from operating cost reductions, mostly in the Bioprocessing Systems Operations segment.
• The Benchtop Laboratory Equipment operations segment is stable and profitable.
• Bioprocessing Systems revenues increased by approximately $323,700 in the year ended December 31, 2024, principally from the new DOTS MPS product.
• The gross profit percentage for the three months ended March 31, 2025, increased to 42.2% from 41.9% in the prior year, primarily due to a higher gross margin percentage in the Bioprocessing Systems Operations.
• General and administrative expenses decreased by $270,500 (17.8%) for the three months ended March 31, 2025, due to decreased employee-related costs associated with a reduction in force in the Bioprocessing Systems Operations.
• General and administrative expenses decreased by $595,200 (11.0%) for the year ended December 31, 2024, due to decreased non-cash stock-based compensation expenses.
• Selling expenses decreased by $1,734,800 (32.3%) for the year ended December 31, 2024, due to decreased non-cash stock-based compensation expenses and reduction of sales and marketing employees in Bioprocessing Systems Operations.
• Research and development expenses decreased by $58,700 (8.3%) for the three months ended March 31, 2025, due to the reduction of R&D expenditures in the Bioprocessing Systems Operations.
• Research and development expenses decreased by $660,100 (18.5%) for the year ended December 31, 2024, due to cost reductions in Bioprocessing Systems Operations and completion of a new VIVID automated pill counter in Benchtop Laboratory Equipment Operations.

Negatives

• The company has a history of losses and expects to incur future operating losses for the foreseeable future, with an accumulated deficit of $35,709,000 as of March 31, 2025.
• Current operating cash flow, cash and investment securities on hand, and available line of credit are not sufficient to fund cash requirements over the next twelve months, raising substantial doubt about the company's ability to continue as a going concern.
• Net revenues decreased by 3.1% for the three months ended March 31, 2025, and by 3.6% for the year ended December 31, 2024.
• Bioprocessing Systems Operations revenues decreased by $182,600 for the three months ended March 31, 2025.
• Benchtop Laboratory Equipment operations experienced a decrease of $722,600 in net revenue for the year ended December 31, 2024, primarily due to reduced Torbal division sales (VIVID pill counter) impacted by new regulations (DIR fees) causing financial hardships for independent pharmacies.
• Genie division sales decreased by approximately 4% for the year ended December 31, 2024, due to overall market softness in demand for laboratory equipment.
• The gross profit percentage for the year ended December 31, 2024, decreased to 44.2% from 45.9% in the prior year, primarily due to increased cost of materials, labor, and fixed overhead for the Benchtop Laboratory Equipment Operations.
• Net cash used in operating activities was $1,331,100 for the three months ended March 31, 2025, and $3,683,500 for the year ended December 31, 2024.
• The company's Common Stock trades on the Over-the-Counter Bulletin Board and has historically been thinly traded, leading to high volatility and potentially impairing the value of shares and the company's ability to raise capital.
• One benchtop laboratory equipment product, the Vortex-Genie 2 Mixer, accounts for a substantial portion of the company's total net revenues (34% for Q1 2025, 33% for FY 2024, 32% for FY 2023) and Benchtop Laboratory Equipment sales (36% for Q1 2025, 38% for FY 2024, 36% for FY 2023), indicating high product concentration risk.
• The company is a small participant in highly competitive, mature industries (Benchtop Laboratory Equipment) and the bioprocessing industry, facing significantly larger competitors with greater resources.
• Bioprocessing products are complex, have taken longer to develop than previously anticipated, and are subject to beta testing and adoption by end users, which could result in further delays.
• The company relies heavily on outside suppliers for components, with a dependence on a few suppliers and risks related to long lead times, foreign production, and potential tariffs, which could halt production.
• The company has no patent protection for its principal Benchtop Laboratory Equipment product, the Vortex-Genie 2 Mixer, or most Torbal products, making them vulnerable to competition.
• The company is exposed to foreign exchange rate risk (transactional and translational) due to its Bioprocessing Systems Operations being substantially located in Germany.
• Sales are dependent on customers' ability to secure funding, including government grants, which can be negatively impacted by economic conditions, budgetary constraints, and geopolitical factors.
• The high value of the U.S. dollar relative to foreign currencies can negatively impact overseas sales, as products become more expensive for international customers.
• Higher material and transportation costs have resulted in significantly higher component costs, which could negatively affect future gross margins if not passed on to customers.
• The company does not anticipate declaring or paying any cash dividends for the foreseeable future, limiting stockholder returns to stock appreciation.

Risks

• The company has limited financial resources and may need to raise additional funding; inability to raise capital could force delays, reductions, or elimination of product discovery, development, or commercialization programs.
• Future funding requirements are substantial and depend on factors such as the scope, progress, timing, costs, and results of product candidates, ability to enter collaborations, number of future product candidates, costs of sales/marketing/manufacturing, effect of competing developments, headcount growth, and intellectual property costs.
• Raising additional capital through equity sales may dilute existing stockholders' ownership interests, and debt financing may impose restrictive covenants.
• The company has a history of losses and expects to incur future losses, particularly as the Bioprocessing Systems operations grow, and may never achieve or sustain profitability.
• Failure to maintain proper and effective internal control over financial reporting could impair the ability to produce accurate and timely financial statements, harming operating results and stock value.
• A limited public market for the company's Common Stock and the potential for an inactive trading market may impair the value of shares and the ability to sell them or raise capital.
• The commercial success of bioprocessing products largely depends on attaining significant market acceptance, which is uncertain in a relatively new and rapidly innovating market.
• Inability to obtain and maintain patent and other intellectual property protection for new bioprocessing products, or insufficient breadth of protection, could allow competitors to develop similar products.
• Inadequate protection of trademarks and trade names could hinder name recognition and adversely affect the business.
• The loss of services from key management personnel (Helena Santos, Robert Nichols, Karl Nowosielski, Daniel Donadille, John A. Moore) could seriously harm the ability to implement business strategy effectively.
• Inability to retain, fully utilize, or hire additional qualified personnel, especially in the bioprocessing sector, could impede effective growth.
• Heavy dependence on international operations, particularly the Bioprocessing Systems Operations in Germany, poses inherent risks in internal controls and exposure to differing laws and regulations.
• Failure to successfully manage any experienced growth could place significant strain on management and administrative, operational, and financial resources.
• The company's growth strategy is based on certain assumptions regarding the bioprocessing market (estimated TAM of $26 billion, SAM of $2.1 billion), which may prove incorrect, adversely impacting the business if the market is smaller or prices are lower than estimated.
• Dependence on major customers (two customers accounted for >=10% of Q1 2025 revenue; top three Benchtop customers 24% of FY 2024 sales) poses a risk of material reduction in sales if these relationships are not retained.
• One benchtop laboratory equipment product, the Vortex-Genie 2 Mixer, accounts for a substantial portion of revenues, creating product concentration risk.
• The company is a small participant in its industries, facing significantly larger competitors with greater resources and constant new entrants.
• The ability to grow and compete effectively depends on the ability to develop and market new products, which is uncertain, especially given the reliance on distributors for Benchtop Laboratory Equipment.
• Bioprocessing products are complex and have taken longer to develop than anticipated, with potential for further delays due to beta testing and design changes.
• Exposure to foreign exchange rate risk (transactional and translational) due to international operations may negatively affect financial performance.
• The company is subject to general economic, political, and social factors that can affect customer funding, including government grants, and tariffs imposed by importing countries.
• Higher material and transportation costs could have a negative effect on future gross margins if the company is unable to pass such cost increases to its customers.
• Heavy dependence on outside suppliers for components, with reliance on a few suppliers and risks of supply shortages due to long lead times and foreign production issues.
• Limited patent protection for principal Benchtop Laboratory Equipment products and the risk that existing patents for Bioprocessing Operations may not provide competitive advantages or may be challenged.
• The company intends to retain future earnings for business development and does not anticipate declaring or paying any cash dividends for the foreseeable future, limiting stockholder returns to stock appreciation.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future as expenses related to the growth and expansion of its Bioprocessing Systems operations are anticipated to exceed revenues. Future funding requirements are substantial, and the ability to conduct additional research and development and commercialization efforts depends on funding availability. The company aims to retain future earnings for business development and does not anticipate paying cash dividends.

Management Comments

• "We believe that we will need to continue to invest substantial capital into such programs in the foreseeable future." (referring to bioprocessing product development and commercialization)
• "We expect our total operating expenses to continue to be material in connection with our ongoing activities, particularly as we continue our emphasis on the bioprocessing sector."
• "Our Benchtop Laboratory Equipment segment comprising the Company’s legacy products plus the weighing, measurement, and pill counting products is stable and profitable, but the Company believes there are greater growth opportunities in our Bioprocessing Systems segment, as part of a large and expanding synthetic biology market sector worldwide."
• "Management has developed a strategic plan to secure such resources for the Company which may include capital from management and significant shareholders sufficient to meet its operating expenses and third-party equity and/or debt financing and exploring the sale of certain assets."

Industry Context

Scientific Industries operates in two distinct segments: the mature and competitive Benchtop Laboratory Equipment industry and the rapidly innovating, expanding Bioprocessing Systems market, which is part of the larger synthetic biology sector. While the Benchtop segment provides stable, profitable revenue, the company's strategic focus and investment are heavily skewed towards the Bioprocessing segment, where it is a small participant competing against significantly larger, established companies. The bioprocessing market is characterized by rapid innovation and uncertainty, requiring substantial R&D and market acceptance efforts. The company's estimates for the bioprocessing market (TAM $26 billion, SAM $2.1 billion) indicate a significant perceived opportunity, but also highlight the speculative nature of its growth strategy in this area.

Comparison to Industry Standards

• The Benchtop Laboratory Equipment industry is highly competitive and mature, with Scientific Industries being a small participant compared to substantially larger competitors with greater financial, production, and marketing resources.
• New entrants, including those offering products imported from China, compete on price in the vortex mixer market, a competitive challenge Scientific Industries cannot match.
• The Torbal line of products also faces significant competition from well-known brands in its industry.
• The Bioprocessing Systems operations are in a start-up phase within an industry dominated by several significantly larger companies.
• The document cites industry reports from Pharma Intelligence UK Limited (a Citeline company, April 2022) and McKinsey & Company (October 2022) for its market size estimates (TAM $26 billion, SAM $2.1 billion), indicating an awareness of broader industry trends and market potential in bioprocessing.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Face potential for significant dilution from future capital raises; the limited public market and high volatility could impair their ability to sell shares; no anticipated cash dividends mean returns are limited to stock appreciation. The current offering is a resale by selling stockholders, meaning no direct proceeds to the company from these sales.
• Employees: Experienced a reduction in force in Bioprocessing Systems Operations; the intense competition for highly skilled personnel in the industry could impact the company's ability to retain and motivate existing employees and hire new ones.
• Customers: Potential negative impact from reduced sales of Torbal division products due to new regulations (DIR fees) affecting independent pharmacies; overall market softness in demand for laboratory equipment could affect sales.
• Suppliers: The company's heavy dependence on outside suppliers for components, with reliance on a few suppliers and risks related to foreign production and potential tariffs, could lead to supply shortages affecting production.
• Creditors: The explicit 'going concern' warning indicates potential challenges in meeting financial obligations without securing additional funding, which could impact creditors' confidence and terms.

Next Steps

• Continue to invest substantial capital into bioprocessing product development and commercialization programs.
• Establish a commercialization strategy for bioprocessing products.
• Develop new products and technologies, primarily related to bioprocessing.
• Obtain further funding through public or private equity offerings, debt financings, collaborations, licensing arrangements, product line divestitures, or other sources.
• Expand facilities, augment operational, financial, and management systems, and hire and train additional qualified personnel to manage growth.
• Continue to invest in the development and marketing of new Benchtop Laboratory Equipment products to increase revenues and reduce dependence on the Vortex-Genie 2 Mixer.
• Management will adjust the valuation allowance for deferred tax assets if the determination of realizability changes in the future.

Key Dates

Recommendation

Keywords

Scientific Industries, Bioprocessing Systems, Benchtop Laboratory Equipment, SEC Filing, S-1/A, Common Stock, Private Placement, Warrants, Going Concern, Liquidity, Net Loss, Revenue, Risk Factors, Intellectual Property, Market Acceptance, Supply Chain, Foreign Exchange Risk, Corporate Governance, SCND, Laboratory Equipment, Biotechnology